Re­vance touts first ther­a­peu­tic in­di­ca­tion for Botox ri­val Daxxi­fy in cer­vi­cal dys­to­nia

Re­vance Ther­a­peu­tics se­cured an FDA ap­proval on Mon­day for its Botox ri­val Daxxi­fy in cer­vi­cal dys­to­nia, mark­ing the drug’s first ther­a­peu­tic in­di­ca­tion.

Daxxi­fy was ap­proved last year as a long-last­ing neu­ro­mod­u­la­tor for the treat­ment of mod­er­ate to se­vere glabel­lar lines, bet­ter known as frown lines. The lat­est ap­proval ex­pands Daxxi­fy’s reach to adults with cer­vi­cal dys­to­nia, a rare neu­ro­log­i­cal con­di­tion in which the neck mus­cles in­vol­un­tar­i­ly con­tract, caus­ing ab­nor­mal move­ments and pain.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER